Heightened scrutiny of SEC disclosures regarding the drug development process has left some life science companies and their executives in the cross hairs of the SEC and shareholders. In a March 2015 speech, the SEC’s Enforcement Director stated, “Accuracy of reporting in your dealings with the FDA is critical to getting investors the information they need. FDA dealings and approvals are the lifeblood of your business and are so important to investment decisions.”
Join Pepper attorneys Aline Fairweather, Scott R. Jones, Judith L. O'Grady and Gay Parks Rainville and Matt Gilman, Associate General Counsel at Bioverativ Therapeutics, Inc., as they discuss the recent uptick in SEC enforcement actions and shareholder lawsuits premised on misrepresentations or omissions regarding the drug development process and the specific types of disclosures that are garnering heightened scrutiny.
This seminar is approved for one substantive CLE credit in New York.
Pepper Hamilton's New York Office
The New York Times Building
620 Eighth Avenue, 37th Fl.
New York, NY 10018-1405
There is no cost to attend.